If you've started waking up at 2 or 3 in the morning, wide awake, sometimes sweating, brain running, and nobody has given you a satisfying answer for why, this page is worth reading. It covers one specific piece of the sleep disruption puzzle that doesn't get enough attention: growth hormone.
Why sleep changes as you age
Growth hormone (GH) is a repair hormone. It doesn't just affect muscle or metabolism; it plays a central role in how your body recovers during sleep. GH pulses during the deep stages of sleep, triggering tissue repair, cellular recovery, and immune regulation. Those pulses are part of what makes deep sleep feel restorative.
The problem: GH output drops significantly with age. By your 40s and 50s, your body is producing a fraction of what it did in your 20s. This decline accelerates around perimenopause and menopause, when hormonal changes compound the effect. Less GH means less deep sleep. Less deep sleep means more surface waking, often at the same time each night, when the GH pulse that would normally carry you through simply isn't there.
This is why sleep disruption is so common in perimenopause and menopause, and why the usual advice (magnesium, better sleep hygiene, cutting caffeine) often doesn't fully address it. It's not just lifestyle. It's biology.
What GH peptides are
GH peptides are research compounds that signal the pituitary gland to produce and release more of your own growth hormone. They don't introduce synthetic GH into your system. Instead, they work upstream of it, prompting your pituitary to amplify the GH it's still capable of producing.
This distinction matters because your pituitary's natural feedback loops stay intact. The system can still respond to signals telling it to dial back if levels get too high. That's different from exogenous (synthetic) GH, where that feedback is bypassed entirely.
Two GH peptides have become among the most discussed in the context of sleep and aging: CJC-1295 No DAC and Ipamorelin.
CJC-1295 No DAC and Ipamorelin: why they're almost always discussed together
These two peptides act on different receptor pathways, which is why researchers study them as a pair rather than separately.
CJC-1295 No DAC is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary and amplifies the natural GH pulses your body produces. The "No DAC" part refers to a specific modification worth understanding: the version with DAC (Drug Affinity Complex) has a much longer half-life and creates a more sustained, elevated GH level. The No DAC version produces a shorter, sharper pulse that more closely mimics your body's natural rhythm. For sleep applications, that pulse pattern matters, and No DAC is generally what researchers focus on.
Ipamorelin acts on ghrelin receptors (ghrelin is a hunger-signaling hormone that also triggers GH release) to trigger a separate GH pulse through a complementary pathway. It's considered selective, meaning it doesn't significantly stimulate cortisol or prolactin release the way some older GH-releasing compounds did. That selectivity is part of why it receives attention in research on sleep and aging.
Used together, CJC-1295 No DAC and Ipamorelin are thought to produce a more complete signal to the pituitary than either would alone. They hit two separate receptor systems, and the combined effect is greater than either peptide in isolation. This is the mechanistic rationale for pairing them, and it's well-supported in the literature even where clinical data in humans is still thin.
What the research actually shows
The honest answer: promising, but early.
Animal studies show increased GH output and improved deep sleep duration with GHRH-based peptides. Human studies on this specific combination are smaller and less controlled than what you'd see for an FDA-approved drug. What researchers have is solid mechanistic understanding, encouraging early human data, and a consistent signal from clinicians working in peptide therapy.
What the research doesn't yet show is large, long-term randomized trials in perimenopausal women specifically. That gap is worth knowing about. The mechanism is real and well-characterized. The clinical evidence at scale is still catching up.
The anecdotal signal from the research and clinical community is significant enough that this combination has become one of the most discussed pairings in the peptide space. But "discussed" and "proven" are different things, and this page will not conflate them.
A note on quality and sourcing
Research peptides aren't regulated the same way pharmaceuticals are, which means the quality differences between vendors are real. When comparing prices, look for suppliers that provide third-party certificates of analysis (COAs) from independent labs, and verify that testing covers purity, not just identity. A cheap peptide of uncertain purity isn't a good deal.
The Peptide Price Lab compare tool shows current per-mg pricing across vetted vendors for both CJC-1295 No DAC and Ipamorelin, with COA verification status included, so you can compare on quality and price together. If you're looking at the pre-mixed blend, you can compare that too. See current prices across vendors.
Where to go from here
If you want to go deeper on the research, the CJC-1295 and Ipamorelin research notes pages cover the study landscape in more detail, including specific citations and mechanism breakdowns.
If you're new to peptides and want to understand what "research use only" actually means before going further, this guide on the research use only label is a good place to start.